Last updated: January 28, 2026
Sponsor: JW Pharmaceutical
Overall Status: Active - Recruiting
Phase
3
Condition
Dysfunctional Uterine Bleeding
Heavy Bleeding / Heavy Periods
Menstrual Disorders
Treatment
KLH-2109+ Leurprorelin acetate Placebo
KLH-2109 Placebo + Leurprorelin acetate
Clinical Study ID
NCT07378098
JW25301
Ages > 19 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Individuals diagnosed with uterine fibroids
Exclusion
Exclusion Criteria:
Metrorrhagia or anovulatory bleeding
Patients with a history of total hysterectomy or bilateral oophorectomy
Study Design
Total Participants: 254
Treatment Group(s): 2
Primary Treatment: KLH-2109+ Leurprorelin acetate Placebo
Phase: 3
Study Start date:
January 26, 2026
Estimated Completion Date:
September 03, 2028
Study Description
Connect with a study center
Asan Medical Center
Seoul 1835848,
South KoreaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.